GLP1R AgonistThe Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes

Sponsor:

Mayo Clinic

Code:

NCT06976619

Conditions

Type 1 Diabetes

Type 2 Diabetes

Eligibility Criteria

Sex: All

Age: 25 - 70

Healthy Volunteers: Not accepted

Interventions

Liraglutide Pen Injector

Saline Injections

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-24. This information was provided to ClinicalTrials.gov by Mayo Clinic on 2025-10-14.